Fight to protect NIH funding and biomedical research from Trump-era cuts.

I made a commitment early on that I would tear up Trump’s budget and write a new one.

Murray reiterates her commitment to replace Trump's budget with one that protects NIH and biomedical research funding.

After Rejecting Trump’s Cuts, In Seattle, Murray Highlights NIH Funding to Protect & Strengthen Washington State’s Biomedical Research Economy - Senator Patty Murray
primary · press_release · model gpt-5.4-mini

Murray said, “I fight for policies to hold giant pharmaceutical companies accountable and lower costs for all of us,” and framed health-care affordability as a central campaign issue.

Campaign material shows Murray explicitly running on fighting for health policy goals, consistent with the promise to fight for biomedical research and NIH-related priorities.

partial same_term

Murray Highlights Lower Prescription Drug and Health Care Costs as Key Campaign Issue
secondary · model gpt-5.4-mini · confidence 58%

Murray said she was “proud to have secured several significant, bipartisan funding increases for NIH over the past few years” and said she would “do everything I can to make sure we don’t take our foot off the gas here.”

This is direct official evidence that Murray was actively working to increase NIH funding and continue championing biomedical research before and during the Trump-era threats.

partial same_term A for effort

Senator Murray Tours Allen Institute, Vows to Continue Championing U.S. and WA Leadership in Biomedical Research
secondary · model gpt-5.4-mini · confidence 91%

Murray said the Trump administration’s NIH indirect-cost cap was “illegal” and would be “nothing short of catastrophic” for lifesaving research; the release says Congress’ bipartisan Labor-HHS appropriations bill prohibits modifications to NIH indirect costs.

Murray publicly opposed a concrete Trump-era NIH cut and pointed to existing appropriations language blocking the change, showing active protection of NIH funding.

partial same_term A for effort

Senator Murray Slams Indirect Cost Rate for NIH as Massive Indiscriminate Cut, Setting Back Progress on Lifesaving Research
secondary · model gpt-5.4-mini · confidence 97%

Section 224 says indirect-cost rules “shall continue to apply to the National Institutes of Health” and Section 240 limits multiyear-award obligations; the NIH title appropriates major funding for NIH accounts, including $48.7 billion for NIH and $226 million for the Cures Act account in the enacted law.

The enacted law preserved NIH indirect-cost protections and provided substantial NIH funding, confirming concrete protection against Trump-era cuts.

delivered same_term

PLAW-119publ75.pdf
secondary · model gpt-5.4-mini · confidence 98%

Murray said that in the government funding bill Trump signed into law on Feb. 3, 2026, she secured $48.7 billion for NIH, a $415 million increase, and that the bill rejected the Trump administration’s proposal to cap indirect cost rates at 15% and other cuts to NIH.

This is the clearest official statement tying Murray’s action to an enacted result: she secured NIH funding and blocked the proposed Trump cuts.

delivered same_term A for effort

After Rejecting Trump’s Cuts, In Seattle, Murray Highlights NIH Funding to Protect & Strengthen Washington State’s Biomedical Research Economy - Senator Patty Murray
primary · model gpt-5.4-mini · confidence 99%

Under the Consolidated Appropriations Act for FY 2026, (P.L. 119-75, Division B, Title II, Sec. 224), the provisions relating to indirect costs apply to NIH awards.

NIH’s current policy page confirms that the FY 2026 appropriations law kept NIH indirect-cost protections in force, which is direct official evidence that the threatened Trump-era NIH cut was blocked and the funding framework remained intact.

delivered same_term

7.4 Reimbursement of Facilities and Administrative Costs
secondary · model gpt-5.4-mini · confidence 97%

In FY 2026, the National Institute of Biomedical Imaging and Bioengineering (NIBIB) received a budget of $440.6 million. This funding was secured under H.R.7148 - Consolidated Appropriations Act, 2026.

A current NIH institute budget page confirms the enacted FY 2026 appropriations are in effect and that NIH biomedical research funding is being carried forward under the 2026 law, consistent with Murray’s promise having been fulfilled in the same term.

delivered same_term

Budget | National Institute of Biomedical Imaging and Bioengineering
secondary · model gpt-5.4-mini · confidence 86%

Under the Consolidated Appropriations Act for FY 2026, (P.L. 119-75, Division B, Title II, Sec. 224), the provisions relating to indirect costs apply to NIH awards.

NIH’s current policy page confirms that the FY 2026 appropriations law kept NIH indirect-cost protections in force, which is direct official evidence that the threatened Trump-era NIH cut was blocked.

delivered same_term

7.4 Reimbursement of Facilities and Administrative Costs
secondary · model gpt-5.4-mini · confidence 97%

Public Law 119-75 enacted the Consolidated Appropriations Act, 2026.

The enacted appropriations law is the operative federal record showing the NIH funding framework and indirect-cost protections were codified into law during Murray’s current Senate term.

delivered same_term

GovInfo
secondary · model gpt-5.4-mini · confidence 98%

Murray said the February 2026 funding law she helped secure provided $48.7 billion for NIH, raised NIH funding by $415 million, rejected the Trump administration's 15% indirect-cost cap, and blocked planned cuts to biomedical research.

Official Senate release tying Murray to enacted NIH funding increases and to rejection of the Trump-era indirect-cost cap and research cuts.

delivered same_term A for effort

After Rejecting Trump’s Cuts, In Seattle, Murray Highlights NIH Funding to Protect & Strengthen Washington State’s Biomedical Research Economy - Senator Patty Murray
primary · model gpt-5.4-mini · confidence 99%

NIH's revised March 2026 policy page says that under Public Law 119-75 the indirect-cost provisions continue to apply to NIH awards.

Current NIH policy confirms the FY 2026 appropriations law kept indirect-cost protections in force for NIH grants.

delivered same_term

7.4 Reimbursement of Facilities and Administrative Costs
secondary · model gpt-5.4-mini · confidence 97%

During the 2026-06-09 to 2026-07-08 lookback window, The Guardian reported that a May 29 OMB proposal would put federal research grants under political-appointee control and that advocates estimated many NIH-funded trials could be discontinued if the rule took effect.

Recent reporting shows a new Trump-era threat to NIH-funded biomedical research remained unresolved after the FY 2026 funding win, though it does not negate the enacted FY 2026 NIH protections.

unresolved same_term

'The purpose of the rule is fascism': scientists fight back against planned Trump research cuts
secondary · model gpt-5.5 · confidence 78%

Axios reported that President Trump's FY 2027 budget proposed a $5 billion NIH cut after Congress had rejected the prior year's much larger NIH reduction, setting up another appropriations fight.

The FY 2027 request shows continued Trump-era pressure on NIH funding, making the broader fight ongoing even though Murray had delivered the FY 2026 protection.

unresolved same_term

Trump budget calls for another sharp cut to NIH
secondary · model gpt-5.5 · confidence 82%

NIH's NIBIB budget page says that in FY 2026 NIBIB received $440.6 million under H.R. 7148, the Consolidated Appropriations Act, 2026, and that the money is primarily used for extramural research.

A current NIH institute page confirms FY 2026 biomedical research funding from the enacted appropriations law is operational.

delivered same_term

Budget | National Institute of Biomedical Imaging and Bioengineering
secondary · model gpt-5.5 · confidence 90%

Public Law 119-75 appropriated FY 2026 NIH institute and center funds, including major accounts for cancer, heart/lung/blood, allergy/infectious diseases, translational sciences, the NIH Office of the Director, and NIH buildings and facilities.

The enacted law provides concrete FY 2026 NIH funding, directly countering the proposed Trump-era NIH reductions for that fiscal year.

delivered same_term

PLAW-119publ75.pdf
secondary · model gpt-5.5 · confidence 98%

Section 224 of Public Law 119-75 kept NIH indirect-cost rules tied to 45 CFR part 75 in place and barred using federal funds to develop or implement a modified approach to those provisions.

The enacted appropriations text blocked the Trump-era NIH indirect-cost cap approach, a central biomedical research funding cut.

delivered same_term

PLAW-119publ75.pdf
secondary · model gpt-5.5 · confidence 99%

Murray said she committed to replacing Trump's budget, won more than a $415 million NIH increase, blocked the indirect-cost cap, rejected the proposed 40 percent medical-research cut, and made Trump sign the funding bill into law.

Murray's official statement ties her concrete appropriations work to the enacted NIH funding increase and rejection of Trump-era biomedical research cuts.

delivered same_term A for effort

After Rejecting Trump’s Cuts, In Seattle, Murray Highlights NIH Funding to Protect & Strengthen Washington State’s Biomedical Research Economy - Senator Patty Murray
primary · model gpt-5.5 · confidence 97%